anti-CD22 CAR T / National Cancer Institute - LARVOL DELTA

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (clinicaltrials.gov) - P1 | N=133 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jun 2040 ➔ Oct 2024

Trial completion • Trial completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22

Deciphering the importance of culture pH on CD22 CAR T-cells characteristics. (PubMed, J Transl Med) - "pH has potential to serve as an informative factor in predicting CAR T-cell quality and clinical outcomes. Thus, its active monitoring during manufacturing may ensure a more effective CAR T-cell product."

CAR T-Cell Therapy • Journal • Hematological Disorders • Hematological Malignancies • Oncology • CD22

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (clinicaltrials.gov) - P1 | N=123 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Active, not recruiting

Enrollment closed • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (clinicaltrials.gov) - P1 | N=123 | Suspended | Sponsor: National Cancer Institute (NCI) | N=208 ➔ 123 | Recruiting ➔ Suspended

Enrollment change • Trial suspension • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22

CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. (PubMed, J Immunother Cancer) - P1 | "With rising incidence of CD19 negative relapse, CD22 CAR T-cells are increasingly important for the treatment of B-cell malignancies. In characterizing hematologic toxicities on CD22 CAR T-cells, we demonstrate that despite endothelial activation, coagulopathy, and cytopenias, neurotoxicity was relatively mild and that CD22 and CD19 expression in the CNS differed, providing one potential hypothesis for divergent neurotoxicity profiles. Systematic characterization of on-target off-tumor toxicities of novel CAR T-cell constructs will be vital as new antigens are targeted."

CAR T-Cell Therapy • Journal • Hematological Disorders • Hematological Malignancies • Immunology • Inflammation • Neutropenia • Oncology • Rare Diseases • Solid Tumor • Thrombocytopenia • CD19 • CD22 • VCAM1

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells. (PubMed, Mol Ther Methods Clin Dev) - "We retrospectively compared clinical outcomes between patients who received cryopreserved versus fresh CAR T cells for treatment of B cell leukemia across two cohorts of pediatric and young adult patients: those who received anti-CD22 CAR T cells and those who received bispecific anti-CD19/22 CAR T cells...Among 19 patients who received anti-CD19/22 CAR T cells (11 cryopreserved and 8 fresh), patients with cryopreserved cells had similar expansion, toxicity incidence, and disease response, with decreased CAR T cell persistence. Overall, our data demonstrate efficacy of cryopreserved CAR T cells as comparable to fresh infusions, supporting cryopreservation, which will be crucial for advancing the field of cell therapy."

CAR T-Cell Therapy • Journal • Hematological Malignancies • Inflammation • Leukemia • Oncology • Pediatrics